Colobreathe colistimethate sodium regulatory update

Forest submitted an MAA to EMEA for Colobreathe colistimethate sodium to treat Pseudomonas aeruginosa pulmonary infection in cystic fibrosis (CF) patients ages 6 years and up. The inhaled dry powder p...